Vicente Miguel, Hodgson John, Massidda Orietta, Tonjum Tone, Henriques-Normark Birgitta, Ron Eliora Z
Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Madrid, Spain.
FEMS Microbiol Rev. 2006 Nov;30(6):841-52. doi: 10.1111/j.1574-6976.2006.00038.x.
While newly developed technologies have revolutionized the classical approaches to combating infectious diseases, the difficulties associated with developing novel antimicrobials mean that these technologies have not yet been used to introduce new compounds into the market. The new technologies, including genomics and structural biology, open up exciting possibilities for the discovery of antibiotics. However, a substantial effort to pursue research, and moreover to incorporate the results into the production chain, is required in order to bring new antimicrobials to the final user. In the current scenario of emerging diseases and the rapid spread of antibiotic resistance, an active policy to support these requirements is vital. Otherwise, many valuable programmes may never be fully developed for lack of "interest" and funds (private and public). Will we react in time to avoid potential disaster?
虽然新开发的技术彻底改变了对抗传染病的传统方法，但开发新型抗菌药物所面临的困难意味着这些技术尚未用于将新化合物推向市场。包括基因组学和结构生物学在内的新技术为抗生素的发现开辟了令人兴奋的可能性。然而，为了将新型抗菌药物带给最终用户，需要付出巨大努力进行研究，而且要将研究结果纳入生产链。在当前新出现疾病以及抗生素耐药性迅速传播的情况下，支持这些需求的积极政策至关重要。否则，许多有价值的项目可能会因缺乏“兴趣”和资金（私人和公共资金）而永远无法充分发展。我们会及时做出反应以避免潜在灾难吗？
